The federally mandated Institutional Biosafety Committee (IBC) is responsible for the planning and implementation of the campus biosafety program to ensure the health and safety of all personnel working with biohazardous agents. The IBC makes certain that research conducted at the College is in compliance with the NIH Guidelines for Research Involving Recombinant DNA Molecules, Centers for Disease Control and Prevention (CDC) and the Select Agent Rule. The IBC drafts campus biosafety policies and procedures and reviews individual research proposals for biosafety concerns.
The IBC meets every other month (3rd Thursday) and may have additional meetings to review studies qualifying for Full Board review. Studies qualifying for Exempt or Expedited review are considered on an ongoing basis.
The IBC, not the researcher, determines the review level. All applications for review and correspondence with the IBC should be directed to the administrative office of the IBC. For IBC forms and documents, application information, study submission deadlines, administrative concerns, and general inquiries, see additional information below (please note, a login is required).
Associate Professor
School of Medicine
Center for AIDS Health Disparities Research
Associate Vice President for Research and Innovation, Professor of Cancer Biology and Pharmacology
Office for Research and Innovation
Health Disparities Research Center of Excellence, National Center for Medical Education Development & Research